Erratum to: Current Epidemiology and Management of Invasive Candidiasis in Infants

Kanecia O. Zimmerman · P. Brian Smith

Published online: 29 April 2014
© Springer Science+Business Media New York 2014

**Erratum to: Curr Fungal Infect Rep (2014) 8:1–11.
DOI 10.1007/s12281-013-0167-5**

In the subsection “Triazoles,” under the section “Systemic Antifungal Therapy” the following sentence has the incorrect dosage listed:

“Voriconazole is approved in the U.S. for pediatric patients aged 12 years and younger and in Europe for patients 2 years and younger. Posaconazole is approved in the U.S. for pediatric patients aged 13 years and younger, but is not approved for IC in Europe for patients under the age of 18 [105].”

The correct sentence should read:

“Voriconazole is approved in the US for pediatric patients aged 12 years and older, and in Europe for patients aged 2 years and older. Posaconazole is approved in the US for pediatric patients aged 13 years and older, but is not approved for IC in Europe for patients under 18 years of age [105].”

This incorrect dosage appeared in the original version of this article that published in *Current Fungal Infection Reports*, Volume 8, Issue 1 (March 2014).

The online version of the original article can be found at <http://dx.doi.org/10.1007/s12281-013-0167-5>.

K. O. Zimmerman · P. B. Smith (✉)
Duke Clinical Research Institute, Box 17969, Durham,
NC 27715, USA
e-mail: brian.smith@duke.edu